An analysis of patient databases sought to determine which factors may contribute to poor adherence to oral anticancer agents among patients with MM.
Researchers sought to determine the safety and efficacy of posttransplantation cyclophosphamide with tacrolimus as prophylaxis for GVHD in patients with hematologic cancer after allogeneic hematopoietic cell transplantation.
Parsaclisib is a potent, highly selective, next-generation phosphoinositide 3-kinase-delta (PI3K-delta) inhibitor.
Among the TEAEs of clinical interest, the most frequent were infections, bleeding, cardiac events, anemia, and neutropenia and neutrophil count decrease.
Results of a phase 3 trial suggest that brentuximab vedotin (Bv) with doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) should be the new standard frontline therapy among youth with high-risk classic Hodgkin lymphoma (cHL).
Based on preliminary data from this study, sugemalimab was granted breakthrough therapy designation for adult patients with R/R ENKTL in 2021.
At a median follow-up of 12.6 months, the overall response rate was 51.6% and the CR rate was 39.4%.
The median duration of response was not reached at a median follow-up of 26 months.
In CML, second malignancies are rare and trends remain poorly understood.
Of the 65 patients who achieved a complete remission with chemotherapy, 63 remained in remission after whole ventricular radiotherapy and at the final follow-up.
